<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Neurol J</journal-id><journal-id journal-id-type="iso-abbrev">Open Neurol J</journal-id><journal-id journal-id-type="publisher-id">TONEUJ</journal-id><journal-title-group><journal-title>The Open Neurology Journal</journal-title></journal-title-group><issn pub-type="epub">1874-205X</issn><publisher><publisher-name>Bentham Open</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3322431</article-id><article-id pub-id-type="publisher-id">TONEUJ-6-1</article-id><article-id pub-id-type="doi">10.2174/1874205X01206010001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Genetic Screening of the Mitochondrial Rho GTPases MIRO1 and MIRO2 in Parkinson&#8217;s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Anvret</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ran</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Westerlund</surname><given-names>Marie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sydow</surname><given-names>Olof</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Willows</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Olson</surname><given-names>Lars</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Galter</surname><given-names>Dagmar</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Belin</surname><given-names>Andrea Carmine</given-names></name><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden</aff><aff id="aff2"><label>2</label>Present address: Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden</aff><aff id="aff3"><label>3</label>Department of Neurology, Karolinska University Hospital, Stockholm, Sweden</aff><author-notes><corresp id="cor1"><label>*</label>Address correspondence to this author at the Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden; Tel: +46-8-524 870 51; Fax: +46-8-323 742; E-mail: <email xlink:href="andrea.carmine.belin@ki.se">andrea.carmine.belin@ki.se</email></corresp></author-notes><pub-date pub-type="epub"><day>3</day><month>4</month><year>2012</year></pub-date><pub-date pub-type="collection"><year>2012</year></pub-date><volume>6</volume><fpage>1</fpage><lpage>5</lpage><history><date date-type="received"><day>13</day><month>12</month><year>2011</year></date><date date-type="rev-recd"><day>20</day><month>2</month><year>2012</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2012</year></date></history><permissions><copyright-statement>&#169; Anvret <italic>et al</italic>; Licensee <italic>Bentham Open.</italic></copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Anvret</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</uri>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.</license-p></license></permissions><abstract><p>MIRO1 and MIRO2 (mitochondrial Ras homolog gene family, member T1 and T2) also referred to as RHOT1 and RHOT2, belong to the mitochondrial Rho GTPase family and are involved in axonal transport of mitochondria in neurons. Because mitochondrial dysfunction is strongly implicated in Parkinson&#8217;s disease (PD), <italic>MIRO1 </italic>and <italic>MIRO2 </italic>can be considered as new candidate genes for PD. We analyzed two non-synonymous polymorphisms and one synonymous polymorphism in <italic>MIRO1 </italic>and two non-synonymous polymorphisms in <italic>MIRO2, </italic>in a Swedish Parkinson case-control material consisting of 241 patients and 307 neurologically healthy controls. None of the analyzed polymorphisms in <italic>MIRO1 </italic>and <italic>MIRO2 </italic>were significantly associated with PD. Although we did not find a significant association with PD in our Swedish case-control material, we cannot exclude these Rho GTPases as candidate genes for PD or other neurodegenerative disorders.</p></abstract><kwd-group><title>Keywords</title><kwd>Association</kwd><kwd>mitochondria</kwd><kwd>single nucleotide polymorphism.</kwd></kwd-group></article-meta></front><body><sec><label>1</label><title>INTRODUCTION</title><p>Degeneration of dopamine (DA) neurons in substantia nigra (SN) pars compacta causes the typical motor symptoms seen in patients with Parkinson&#8217;s disease (PD); resting tremor, rigidity, bradykinesia and postural instability [<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref>]. However, neuropathology in PD is widespread, affecting neurons in areas from the gastrointestinal tract to cerebral cortex [<xref ref-type="bibr" rid="R3">3</xref>]. In accordance with the systemic nature of the disease, there is increasing evidence that mitochondrial dysfunction may underlie some forms of PD [<xref ref-type="bibr" rid="R4">4</xref>-<xref ref-type="bibr" rid="R6">6</xref>]. Mitochondria are essential in all eukaryotic cells for generating ATP, calcium buffering and involvement in programmed cell death [<xref ref-type="bibr" rid="R7">7</xref>-<xref ref-type="bibr" rid="R9">9</xref>]. To adapt to cellular demands mitochondria undergo fusion and fission, two opposing processes that exist in equilibrium [<xref ref-type="bibr" rid="R10">10</xref>]. The mitochondrial network is very dynamic in neurons [<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R12">12</xref>] and the rate of mitochondrial fusion and fission is high [<xref ref-type="bibr" rid="R13">13</xref>]. Recruitment of mitochondria to specific neuronal compartments has been shown to be an active ATP consuming process [<xref ref-type="bibr" rid="R14">14</xref>]. In support of a mitochondrial involvement in PD, the metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which is 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>), is a neurotoxin and inhibits the mitochondrial respiratory chain complex I, which causes degeneration of DA neurons in SN [<xref ref-type="bibr" rid="R15">15</xref>]. Another inhibitor of complex I is the pesticide rotenone. In rodents it causes selective degeneration of DA neurons, as well as other neurons to a lesser extent, thereby resembling the pathology of PD [<xref ref-type="bibr" rid="R16">16</xref>]. Complex I activity has been found to be reduced in SN and in platelets from PD patients [<xref ref-type="bibr" rid="R17">17</xref>]. </p><p>Different polymorphisms in mtDNA have been reported to be associated with both increased and decreased risk of PD [<xref ref-type="bibr" rid="R18">18</xref>]. We and others have found associations between PD risk and two nuclear genes involved in mitochondrial maintenance, <italic>MTIF3</italic> (mitochondrial translation initiation factor 3) and <italic>POLG1 </italic>(DNA polymerase gamma 1). <italic>MTIF3</italic> is part of the initiation complex formation on the mitochondrial 55S ribosome and regulates translation of proteins within mitochondria [<xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R20">20</xref>]. A synonymous single nucleotide polymorphism (SNP) in <italic>MTIF3</italic>, rs7669, has been reported to be associated with PD in cohorts with different geographical origin [<xref ref-type="bibr" rid="R21">21</xref>-<xref ref-type="bibr" rid="R23">23</xref>]. <italic>POLG1</italic> is important for replication and repair of the mitochondrial genome [<xref ref-type="bibr" rid="R24">24</xref>]. Variations in length of the polyglutamine tract of <italic>POLG1</italic> have been found to associate with PD by a number of groups in different geographical regions [<xref ref-type="bibr" rid="R25">25</xref>-<xref ref-type="bibr" rid="R27">27</xref>].</p><p>Several of the PARK genes identified by linkage studies have been reported to influence mitochondria in different ways. Mutations in PTEN induced putative kinase 1 (<italic>PINK1</italic>) at PARK6, reported to regulate mitochondrial fission, cause early-onset familial PD [<xref ref-type="bibr" rid="R28">28</xref>]. Mutations in <italic>Parkin</italic> at PARK2 have been reported to cause autosomal recessive early-onset Parkinsonism [<xref ref-type="bibr" rid="R29">29</xref>]. Parkin acts in a similar way as PINK1 [<xref ref-type="bibr" rid="R30">30</xref>] and is believed to be recruited from the cytoplasm by PINK1 to initiate autophagic degradation of impaired mitochondria [<xref ref-type="bibr" rid="R31">31</xref>]. <italic>DJ-1</italic> at PARK7 causes autosomal recessive early-onset Parkinsonism [<xref ref-type="bibr" rid="R32">32</xref>] and is suggested to operate in a parallel pathway to that of PINK1/Parkin to maintain mitochondrial function in oxidative environments [<xref ref-type="bibr" rid="R33">33</xref>]. Pink1 has been shown to be part of a mitochondrial multi-protein complex together with the atypical GTPases Miro1 and Miro2 (mitochondrial Ras homolog gene family, member T1 and T2) and the adaptor protein Milton [<xref ref-type="bibr" rid="R34">34</xref>]. This suggests that Pink1 also plays a role in mitochondrial trafficking. </p><p>Miro1 and Miro2, also referred to as Rhot1 and Rhot2, belong to the mitochondrial Rho GTPase family and are involved in axonal transport of mitochondria [<xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R36">36</xref>]. Miro1 and Miro2 were first identified in yeast [<xref ref-type="bibr" rid="R37">37</xref>] and later described to share similarities with Rho GTPases [<xref ref-type="bibr" rid="R38">38</xref>]. Miro proteins have a C-terminal domain locating them to the mitochondrial outer membrane, as well as two GTPase domains and two calcium binding EF-hands [<xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R37">37</xref>]. Calcium binding to the EF-hands regulates the trafficking of mitochondria along microtubules [<xref ref-type="bibr" rid="R39">39</xref>,<xref ref-type="bibr" rid="R40">40</xref>]. </p><p>Based on the finding that mitochondrial dysfunction has been implicated in PD [<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R41">41</xref>], the importance of Miro1 and Miro2 in mitochondrial transport [<xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R36">36</xref>] and the link between Miro and Pink1 [<xref ref-type="bibr" rid="R34">34</xref>], we analyzed SNPs in <italic>MIRO1</italic> and <italic>MIRO2</italic> with regard to PD. We hypothesized that genetic variations in functionally important regions of these two genes might lead to disturbed mitochondrial trafficking, fusion and/or fission disturbances in neurons and hence increase the risk of neurodegenerative events, such as those observed in PD. We therefore investigated the possible association of five SNPs located in functional regions of the proteins MIRO1 and MIRO2. The SNPs were selected from the NCBI database and screened in a Swedish Parkinson case-control material (see Table <bold><xref ref-type="table" rid="T1">1</xref></bold>). Three SNPs were selected in <italic>MIRO1</italic>, one synonymous SNP in the GTPase domain (rs16967164) and two non-synonymous SNPs in each of the two EF-hands (rs28630420, rs34538349). The other two SNPs were non-synonymous SNPs located in one of the EF-hand domains of <italic>MIRO2</italic> (rs1139897 and rs3743912). </p></sec><sec><label>2</label><title>MATERIALS AND METHODOLOGY</title><sec><label>2.1</label><title>Subjects</title><p>A Swedish PD case-control material of Caucasian origin was genotyped for three SNPs in <italic>MIRO1</italic> and two in <italic>MIRO2</italic> (see Table <bold><xref ref-type="table" rid="T1">1</xref></bold>). The PD material consisted of 241 individuals from the Stockholm area (mean age 67.0 years, 60.9% men). The DNA was obtained after informed oral and written consent and approval of the local ethics committee, Regionala etikpr&#246;vningsn&#228;mnden, Stockholm, Sweden. All PD subjects met the United Kingdom Parkinson's Disease Society Brain Bank Criteria for PD except that more than one affected first, second or third degree relative was allowed [<xref ref-type="bibr" rid="R42">42</xref>]. Control subjects consisted of 307 neurologically healthy spouses of PD patients and individuals from the SNAC-K project (The Swedish National Study on Aging and Care in Kungsholmen) from the Stockholm area (mean age 64.2 years, 40.4% men). DNA was extracted from blood according to standard protocols. </p></sec><sec><label>2.2</label><title>Genotyping</title><p>The SNPs were genotyped with predesigned TaqMan SNP Genotyping Assays: C_1630552_10 (rs16967164), C_60583023_10 (rs28630420), C_25937296_10 (rs3743912), C_2463996_1_ (rs1139897) and a custom designed assay (rs34538349) using a fast real-time PCR instrument (ABI 7500 FAST Real-Time PCR, Applied Biosystems, Foster City, CA, USA). The TaqMan assay contained primers and 5&#180; fluorescently labeled (FAM and VIC) minor groove binding probes (20&#215;) for detection of the SNPs. Allelic discrimination was run with pre- and custom-designed primers and probes, genotyping master mix (TaqMan<sup>&#174;</sup>, Applied Biosystems, Foster City, CA, USA) and 10-20 ng of genomic DNA in a total reaction volume of 10 &#181;l mixed in transparent 96-well plates. The polymerase chain reaction (PCR) conditions followed the recommendations of default settings for the SNP assay, except that the number of cycles were set to 55 and run at 92&#176;C for 15 s. The ramp speed was set to standard. A post-PCR read was done for allelic discrimination using appropriate software (SDS version 2.0.4) supplied with the instrument. To test for genotyping errors we used water as negative controls and re-genotyped randomly chosen samples to confirm the results. Case-control analysis between individual sequence variants in <italic>MIRO1</italic> and <italic>MIRO2</italic> were performed using a Chi-square (&#967;<sup>2</sup>) test [<xref ref-type="bibr" rid="R43">43</xref>]. Three PD patients previously known to carry the pathogenic G2019S mutation in leucine-rich repeat kinase 2 (<italic>LRRK2)</italic> were excluded from the association analysis. Distribution of genotypes in controls was tested for consistency with the Hardy-Weinberg equilibrium. Statistical significance was defined as p&lt; 0.05. </p></sec></sec><sec><label>3</label><title>RESULTS</title><p>The results from the TaqMan genotyping of the five SNPs in <italic>MIRO1</italic> and <italic>MIRO2</italic> are presented in Table <bold><xref ref-type="table" rid="T2">2</xref></bold>. We did not find any genotypic or allelic (data available upon request) association of the <italic>MIRO1</italic> or <italic>MIRO2</italic> SNPs screened in our Swedish Parkinson case-control material. The observed frequencies of the controls were in agreement with the Hardy-Weinberg equilibrium (data not shown). For two of the SNPs in <italic>MIRO1 (</italic>rs28630420, rs34538349) we only observed the wild-type genotype. </p><p>To investigate if any of the SNPs had a possible effect on age of onset we stratified the material into early disease onset (&#8804;50 years) or late disease onset (&gt;50 years) and compared genotype and allele frequencies. However, such stratification did not reveal any significant associations with disease at genotype or allele (data available upon request) levels, as shown in Table <bold><xref ref-type="table" rid="T3">3</xref></bold>. </p></sec><sec><label>4</label><title>DISCUSSION</title><p>Dysfunctional mitochondria may be the cause or the consequence of DA neuron degeneration in PD. This is the first genetic study analyzing possible links between the two GTPases <italic>MIRO1</italic> and <italic>MIRO2</italic> and disease in general and neurodegenerative disease in particular. Two functionally important regions in the two Miro proteins are the two GTPase domains and two calcium binding EF-hands [<xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R37">37</xref>]. Another protein with a GTPase domain linked to PD is leucine-rich repeat kinase 2 (LRRK2), a large protein with multiple domains, including functional Roc GTPase and a protein kinase domain. Several mutations in the kinase domain of <italic>LRRK2 </italic>are associated with both sporadic and familial PD [<xref ref-type="bibr" rid="R44">44</xref>]. Recently, a new mutation (N1437S) localized within the GTPase domain of LRRK2 (PARK8) was found to cosegregate with PD [<xref ref-type="bibr" rid="R45">45</xref>]. Furthermore, it has been suggested that the GTPase domain may contribute to the toxicity of LRRK2 [<xref ref-type="bibr" rid="R46">46</xref>]. Interestingly, knockdown of lrk-1, the ortholog of LRRK2 in <italic>C. elegans</italic>, has been reported to lead to reduced survival and is associated with dysfunctional mitochondria [<xref ref-type="bibr" rid="R47">47</xref>]. There are no reports on proteins with EF-hand domains being linked to PD today. </p><p>It has been shown that all domains of Gem1P (i.e. yeast Miro) are needed for proper mitochondrial morphology [<xref ref-type="bibr" rid="R37">37</xref>]. Loss-of-function mutations in the Miro GTPase in <italic>Drosophila melanogaster </italic>lead to impaired locomotion and premature death of the flies [<xref ref-type="bibr" rid="R48">48</xref>]. Based on these findings we selected polymorphisms that are located in functional regions in MIRO1 and MIRO2 to analyze possible association with risk for neurodegeneration. The three selected <italic>MIRO1</italic> SNPs are localized in one of the GTPase domains (rs16967164) and in each of the two EF-hands (rs28630420, rs34538349). The two SNPs in <italic>MIRO2</italic> (rs1139897 and rs3743912) are situated in one of the EF-hand domains. We did not find association with any of the selected SNPs in our Swedish case-control material. For two of the SNPs in <italic>MIRO1</italic> (rs28630420 and rs34538349) we only detected the wild-type genotype in our material of cases and controls. Thus these two mutations tend to be very rare in the area from which our DNA samples have been collected. The results after stratification of the material regarding age of onset did not reveal any age-of-onset association with any of the detected polymorphisms. Further genetic analysis and functional studies in disease are however needed before one can exclude <italic>MIRO1</italic> and <italic>MIRO2</italic> as potential candidate genes for PD.</p></sec><sec><title>CONCLUSION</title><p>Genetic variation in <italic>MIRO1</italic> and <italic>MIRO2</italic> might influence transport of mitochondria along microtubules, leading to reduced local energy production which can lead to degeneration of DA neurons. Although we did not find a significant association with PD and the selected polymorphisms in <italic>MIRO1</italic> and <italic>MIRO2</italic> in our Swedish case-control material, we cannot exclude these Rho GTPases as candidate genes for PD or other neurodegenerative disorders. </p></sec></body><back><ack><title>ACKNOWLEDGEMENT</title><p>We would like to thank Professor Laura Fratiglioni for providing us with control samples from the Swedish National Study on Aging and Care in Kungsholmen (SNAC-K) project and Doctor Fengqing Xiang for excellent technical assistance. The study was supported by the Swedish Research Council, the Swedish Brain Foundation, Karolinska Institutet Funds, Magnus Bergvalls stiftelse, the Swedish Parkinson Foundation, &#197;ke Wibergs stiftelse and Swedish Brain Power. </p></ack><sec><title>CONFLICT OF INTEREST</title><p>None declared.</p></sec><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Kovari</surname><given-names>E</given-names></name><name><surname>Horvath</surname><given-names>J</given-names></name><name><surname>Bouras</surname><given-names>C</given-names></name></person-group><article-title>Neuropathology of Lewy body disorders</article-title><source>Brain Res Bull</source><year>2009</year><volume>80</volume><fpage>203</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">19576266</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Lees</surname><given-names>AJ</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name></person-group><article-title>Parkinson's disease</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>2055</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">19524782</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Braak</surname><given-names>H</given-names></name><name><surname>de Vos</surname><given-names>RA</given-names></name><name><surname>Bohl</surname><given-names>J</given-names></name><name><surname>Del</surname><given-names>TK</given-names></name></person-group><article-title>Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology</article-title><source>Neurosci Lett</source><year>2006</year><volume>396</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16330147</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Lin</surname><given-names>MT</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name></person-group><article-title>Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases</article-title><source>Nature</source><year>2006</year><volume>443</volume><fpage>787</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">17051205</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Schapira</surname><given-names>AH</given-names></name></person-group><article-title>Mitochondria in the aetiology and pathogenesis of Parkinson's disease</article-title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">18093566</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Vila</surname><given-names>M</given-names></name><name><surname>Ramonet</surname><given-names>D</given-names></name><name><surname>Perier</surname><given-names>C</given-names></name></person-group><article-title>Mitochondrial alterations in Parkinson's disease: new clues</article-title><source>J Neurochem</source><year>2008</year><volume>107</volume><fpage>317</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">18680555</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Bernardi</surname><given-names>P</given-names></name><name><surname>Petronilli</surname><given-names>V</given-names></name><name><surname>Di</surname><given-names>LF</given-names></name><name><surname>Forte</surname><given-names>M</given-names></name></person-group><article-title>A mitochondrial perspective on cell death</article-title><source>Trends Biochem Sci</source><year>2001</year><volume>26</volume><fpage>112</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11166569</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Chan</surname><given-names>DC</given-names></name></person-group><article-title>Mitochondria: dynamic organelles in disease, aging, and development</article-title><source>Cell</source><year>2006</year><volume>125</volume><fpage>1241</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">16814712</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> David</surname><given-names>G</given-names></name><name><surname>Barrett</surname><given-names>EF</given-names></name></person-group><article-title>Stimulation-evoked increases in cytosolic [Ca(2+)] in mouse motor nerve terminals are limited by mitochondrial uptake and are temperature-dependent</article-title><source>J Neurosci</source><year>2000</year><volume>20</volume><fpage>7290</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11007886</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Bereiter-Hahn</surname><given-names>J</given-names></name><name><surname>Voth</surname><given-names>M</given-names></name></person-group><article-title>Dynamics of mitochondria in living cells: shape changes, dislocations, fusion, and fission of mitochondria</article-title><source>Microsc Res Tech</source><year>1994</year><volume>27</volume><fpage>198</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">8204911</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Chen</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name></person-group><article-title>Critical dependence of neurons on mitochondrial dynamics</article-title><source>Curr Opin Cell Biol</source><year>2006</year><volume>18</volume><fpage>453</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16781135</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Hollenbeck</surname><given-names>PJ</given-names></name><name><surname>Saxton</surname><given-names>WM</given-names></name></person-group><article-title>The axonal transport of mitochondria</article-title><source>J Cell Sci</source><year>2005</year><volume>118</volume><fpage>5411</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16306220</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Kuznetsov</surname><given-names>AV</given-names></name><name><surname>Hermann</surname><given-names>M</given-names></name><name><surname>Saks</surname><given-names>V</given-names></name><name><surname>Hengster</surname><given-names>P</given-names></name><name><surname>Margreiter</surname><given-names>R</given-names></name></person-group><article-title>The cell-type specificity of mitochondrial dynamics</article-title><source>Int J Biochem Cell Biol</source><year>2009</year><volume>41</volume><fpage>1928</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">19703655</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Chang</surname><given-names>DT</given-names></name><name><surname>Honick</surname><given-names>AS</given-names></name><name><surname>Reynolds</surname><given-names>IJ</given-names></name></person-group><article-title>Mitochondrial trafficking to synapses in cultured primary cortical neurons</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>7035</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">16807333</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Langston</surname><given-names>JW</given-names></name><name><surname>Ballard</surname><given-names>P</given-names></name><name><surname>Tetrud</surname><given-names>JW</given-names></name><name><surname>Irwin</surname><given-names>I</given-names></name></person-group><article-title>Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis</article-title><source>Science</source><year>1983</year><volume>219</volume><fpage>979</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">6823561</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Greenamyre</surname><given-names>JT</given-names></name><name><surname>MacKenzie</surname><given-names>G</given-names></name><name><surname>Peng</surname><given-names>TI</given-names></name><name><surname>Stephans</surname><given-names>SE</given-names></name></person-group><article-title>Mitochondrial dysfunction in Parkinson's disease</article-title><source>Biochem Soc Symp</source><year>1999</year><volume>66</volume><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">10989660</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> van der Walt</surname><given-names>JM</given-names></name><name><surname>Nicodemus</surname><given-names>KK</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease</article-title><source>Am J Hum Genet</source><year>2003</year><volume>72</volume><fpage>804</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">12618962</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Otaegui</surname><given-names>D</given-names></name><name><surname>Paisan</surname><given-names>C</given-names></name><name><surname>Saenz</surname><given-names>A</given-names></name></person-group><article-title>Mitochondrial polymporphisms in Parkinson's Disease</article-title><source>Neurosci Lett</source><year>2004</year><volume>370</volume><fpage>171</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15488317</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Christian</surname><given-names>BE</given-names></name><name><surname>Spremulli</surname><given-names>LL</given-names></name></person-group><article-title>Evidence for an active role of IF3mt in the initiation of translation in mammalian mitochondria</article-title><source>Biochemistry</source><year>2009</year><volume>48</volume><fpage>3269</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">19239245</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Koc</surname><given-names>EC</given-names></name><name><surname>Spremulli</surname><given-names>LL</given-names></name></person-group><article-title>Identification of mammalian mitochondrial translational initiation factor 3 and examination of its role in initiation complex formation with natural mRNAs</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>35541</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12095986</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Abahuni</surname><given-names>N</given-names></name><name><surname>Gispert</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mitochondrial translation initiation factor 3 gene polymorphism associated with Parkinson's disease</article-title><source>Neurosci Lett</source><year>2007</year><volume>414</volume><fpage>126</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17267121</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Anvret</surname><given-names>A</given-names></name><name><surname>Ran</surname><given-names>C</given-names></name><name><surname>Westerlund</surname><given-names>M</given-names></name><etal/></person-group><article-title>Possible involvement of a mitochondrial translation initiation factor 3 variant causing decreased mRNA levels in Parkinson's disease</article-title><source>Parkinsons Dis</source><year>2010</year><volume>2010</volume><fpage>491751</fpage><pub-id pub-id-type="pmid">20976088</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Behrouz</surname><given-names>B</given-names></name><name><surname>Vilarino-Guell</surname><given-names>C</given-names></name><name><surname>Heckman</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Mitochondrial translation initiation factor 3 polymorphism and Parkinson's disease</article-title><source>Neurosci Lett</source><year>2010</year><volume>486</volume><fpage>228</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">20887776</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Kaguni</surname><given-names>LS</given-names></name></person-group><article-title>DNA polymerase gamma, the mitochondrial replicase</article-title><source>Annu Rev Biochem</source><year>2004</year><volume>73</volume><fpage>293</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">15189144</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Anvret</surname><given-names>A</given-names></name><name><surname>Westerlund</surname><given-names>M</given-names></name><name><surname>Sydow</surname><given-names>O</given-names></name><etal/></person-group><article-title>Variations of the CAG trinucleotide repeat in DNA polymerase gamma (POLG1) is associated with Parkinson's disease in Sweden</article-title><source>Neurosci Lett</source><year>2010</year><volume>485</volume><fpage>117</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">20826197</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Eerola</surname><given-names>J</given-names></name><name><surname>Luoma</surname><given-names>PT</given-names></name><name><surname>Peuralinna</surname><given-names>T</given-names></name><etal/></person-group><article-title>POLG1 polyglutamine tract variants associated with Parkinson's disease</article-title><source>Neurosci Lett</source><year>2010</year></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Luoma</surname><given-names>PT</given-names></name><name><surname>Eerola</surname><given-names>J</given-names></name><name><surname>Ahola</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease</article-title><source>Neurology</source><year>2007</year><volume>69</volume><fpage>1152</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17846414</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Valente</surname><given-names>EM</given-names></name><name><surname>Abou-Sleiman</surname><given-names>PM</given-names></name><name><surname>Caputo</surname><given-names>V</given-names></name><etal/></person-group><article-title>Hereditary early-onset Parkinson's disease caused by mutations in PINK1</article-title><source>Science</source><year>2004</year><volume>304</volume><fpage>1158</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">15087508</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Kitada</surname><given-names>T</given-names></name><name><surname>Asakawa</surname><given-names>S</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><etal/></person-group><article-title>Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism</article-title><source>Nature</source><year>1998</year><volume>392</volume><fpage>605</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9560156</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Poole</surname><given-names>AC</given-names></name><name><surname>Thomas</surname><given-names>RE</given-names></name><name><surname>Andrews</surname><given-names>LA</given-names></name><etal/></person-group><article-title>The PINK1/Parkin pathway regulates mitochondrial morphology</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>1638</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">18230723</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Matsuda</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Shiba</surname><given-names>K</given-names></name><etal/></person-group><article-title>PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy</article-title><source>J Cell Biol</source><year>2010</year><volume>189</volume><fpage>211</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">20404107</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> van Duijn</surname><given-names>CM</given-names></name><name><surname>Dekker</surname><given-names>MC</given-names></name><name><surname>Bonifati</surname><given-names>V</given-names></name><etal/></person-group><article-title>Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36</article-title><source>Am J Hum Genet</source><year>2001</year><volume>69</volume><fpage>629</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">11462174</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Thomas</surname><given-names>KJ</given-names></name><name><surname>McCoy</surname><given-names>MK</given-names></name><name><surname>Blackinton</surname><given-names>J</given-names></name><etal/></person-group><article-title>DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy</article-title><source>Hum Mol Genet</source><year>2010</year><volume>20</volume><issue>1</issue><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">20940149</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Weihofen</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>KJ</given-names></name><name><surname>Ostaszewski</surname><given-names>B</given-names></name><name><surname>Cookson</surname><given-names>M</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Pink1 forms a multi-protein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking</article-title><source>Biochemistry</source><year>2009</year></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Macaskill</surname><given-names>AF</given-names></name><name><surname>Brickley</surname><given-names>K</given-names></name><name><surname>Stephenson</surname><given-names>FA</given-names></name><name><surname>Kittler</surname><given-names>JT</given-names></name></person-group><article-title>GTPase dependent recruitment of Grif-1 by Miro1 regulates mitochondrial trafficking in hippocampal neurons</article-title><source>Mol Cell Neurosci</source><year>2009</year><volume>40</volume><issue>3</issue><fpage>301</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">19103291</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Fransson</surname><given-names>S</given-names></name><name><surname>Ruusala</surname><given-names>A</given-names></name><name><surname>Aspenstrom</surname><given-names>P</given-names></name></person-group><article-title>The atypical Rho GTPases Miro-1 and Miro-2 have essential roles in mitochondrial trafficking</article-title><source>Biochem Biophys Res Commun</source><year>2006</year><volume>344</volume><fpage>500</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">16630562</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Frederick</surname><given-names>RL</given-names></name><name><surname>McCaffery</surname><given-names>JM</given-names></name><name><surname>Cunningham</surname><given-names>KW</given-names></name><name><surname>Okamoto</surname><given-names>K</given-names></name><name><surname>Shaw</surname><given-names>JM</given-names></name></person-group><article-title>Yeast Miro GTPase, Gem1p, regulates mitochondrial morphology <italic>via</italic> a novel pathway</article-title><source>J Cell Biol</source><year>2004</year><volume>167</volume><fpage>87</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">15479738</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Fransson</surname><given-names>A</given-names></name><name><surname>Ruusala</surname><given-names>A</given-names></name><name><surname>Aspenstrom</surname><given-names>P</given-names></name></person-group><article-title>Atypical Rho GTPases have roles in mitochondrial homeostasis and apoptosis</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>6495</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">12482879</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Lewit-Bentley</surname><given-names>A</given-names></name><name><surname>Rety</surname><given-names>S</given-names></name></person-group><article-title>EF-hand calcium-binding proteins</article-title><source>Curr Opin Struct Biol</source><year>2000</year><volume>10</volume><fpage>637</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">11114499</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Macaskill</surname><given-names>AF</given-names></name><name><surname>Rinholm</surname><given-names>JE</given-names></name><name><surname>Twelvetrees</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapses</article-title><source>Neuron</source><year>2009</year><volume>61</volume><fpage>541</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">19249275</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Baron</surname><given-names>M</given-names></name><name><surname>Kudin</surname><given-names>AP</given-names></name><name><surname>Kunz</surname><given-names>WS</given-names></name></person-group><article-title>Mitochondrial dysfunction in neurodegenerative disorders</article-title><source>Biochem Soc Trans</source><year>2007</year><volume>35</volume><fpage>1228</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">17956319</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Daniel</surname><given-names>SE</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><article-title>Parkinson's Disease Society Brain Bank, London: overview and research</article-title><source>J Neural Transm Suppl</source><year>1993</year><volume>39</volume><fpage>165</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">8360656</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Sham</surname><given-names>PC</given-names></name><name><surname>Curtis</surname><given-names>D</given-names></name></person-group><article-title>Monte Carlo tests for associations between disease and alleles at highly polymorphic loci</article-title><source>Ann Hum Genet</source><year>1995</year><volume>59</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">7762987</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Belin</surname><given-names>AC</given-names></name><name><surname>Westerlund</surname><given-names>M</given-names></name></person-group><article-title>Parkinson's disease: a genetic perspective</article-title><source>FEBS J</source><year>2008</year><volume>275</volume><fpage>1377</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">18279377</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Aasly</surname><given-names>JO</given-names></name><name><surname>Vilarino-Guell</surname><given-names>C</given-names></name><name><surname>Dachsel</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease</article-title><source>Mov Disord</source><year>2010</year><volume>25</volume><fpage>2156</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">20669305</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Xiong</surname><given-names>Y</given-names></name><name><surname>Coombes</surname><given-names>CE</given-names></name><name><surname>Kilaru</surname><given-names>A</given-names></name><etal/></person-group><article-title>GTPase activity plays a key role in the pathobiology of LRRK2</article-title><source>PLoS Genet</source><year>2010</year><volume>6</volume><fpage>e1000902</fpage><pub-id pub-id-type="pmid">20386743</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Saha</surname><given-names>S</given-names></name><name><surname>Guillily</surname><given-names>MD</given-names></name><name><surname>Ferree</surname><given-names>A</given-names></name><etal/></person-group><article-title>LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans</article-title><source>J Neurosci</source><year>2009</year><volume>29</volume><fpage>9210</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19625511</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Guo</surname><given-names>X</given-names></name><name><surname>Macleod</surname><given-names>GT</given-names></name><name><surname>Wellington</surname><given-names>A</given-names></name><etal/></person-group><article-title>The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses</article-title><source>Neuron</source><year>2005</year><volume>47</volume><fpage>379</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16055062</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" position="float"><label>Table 1.</label><caption><p>Investigated Polymorphisms in <italic>MIRO1</italic> and <italic>MIRO2</italic>, their Nucleotide Position, Consequence, Genomic Location and Functional Protein Region</p></caption></table-wrap><table-wrap id="T2" position="float"><label>Table 2.</label><caption><p>Genotype Frequencies of <italic>MIRO1</italic> and <italic>MIRO2</italic> Variants in Swedish Patients with Parkinson&#180;s Disease (PD) Compared to Matched Neurologically Healthy Controls Analyzed using a Two-sided Chi-square (&#967;<sup>2</sup>) test</p></caption></table-wrap><table-wrap id="T3" position="float"><label>Table 3.</label><caption><p>Stratification of Parkinson&#8217;s Disease (PD) Cases into Early (&#8804;50 years) and Late Onset (&gt;50 years), Comparing <italic>MIRO1</italic> and <italic>MIRO2</italic> Genotype Frequencies Analyzed using a Two-sided Chi-square (&#967;<sup>2</sup>) Test</p></caption></table-wrap></floats-group></article>